These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23048186)

  • 1. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
    Kievit P; Halem H; Marks DL; Dong JZ; Glavas MM; Sinnayah P; Pranger L; Cowley MA; Grove KL; Culler MD
    Diabetes; 2013 Feb; 62(2):490-7. PubMed ID: 23048186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes: long-acting insulin analogues--are benefits worth the cost?
    Nathan DM
    Nat Rev Endocrinol; 2012 Dec; 8(12):699-700. PubMed ID: 23147577
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
    Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA
    Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
    Chen KY; Muniyappa R; Abel BS; Mullins KP; Staker P; Brychta RJ; Zhao X; Ring M; Psota TL; Cone RD; Panaro BL; Gottesdiener KM; Van der Ploeg LH; Reitman ML; Skarulis MC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1639-45. PubMed ID: 25675384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity.
    Fosgerau K; Raun K; Nilsson C; Dahl K; Wulff BS
    J Endocrinol; 2014 Feb; 220(2):97-107. PubMed ID: 24204009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
    EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential control of metabolic and cardiovascular functions by melanocortin-4 receptors in proopiomelanocortin neurons.
    do Carmo JM; da Silva AA; Rushing JS; Pace B; Hall JE
    Am J Physiol Regul Integr Comp Physiol; 2013 Aug; 305(4):R359-68. PubMed ID: 23842677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice.
    da Silva AA; Freeman JN; Hall JE; do Carmo JM
    Am J Physiol Regul Integr Comp Physiol; 2018 Apr; 314(4):R533-R539. PubMed ID: 29351428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocortin signalling and the regulation of blood pressure in human obesity.
    Greenfield JR
    J Neuroendocrinol; 2011 Feb; 23(2):186-93. PubMed ID: 21062377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options.
    Fani L; Bak S; Delhanty P; van Rossum EF; van den Akker EL
    Int J Obes (Lond); 2014 Feb; 38(2):163-9. PubMed ID: 23774329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin.
    Tallam LS; da Silva AA; Hall JE
    Hypertension; 2006 Jul; 48(1):58-64. PubMed ID: 16754792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
    Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
    Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats.
    Hsiung HM; Hertel J; Zhang XY; Smith DP; Smiley DL; Heiman ML; Yang DD; Husain S; Mayer JP; Zhang L; Mo H; Yan LZ
    Endocrinology; 2005 Dec; 146(12):5257-66. PubMed ID: 16166226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
    Kühnen P; Krude H; Biebermann H
    Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
    Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
    Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.
    Sharma S; Garfield AS; Shah B; Kleyn P; Ichetovkin I; Moeller IH; Mowrey WR; Van der Ploeg LHT
    Molecules; 2019 May; 24(10):. PubMed ID: 31100979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
    Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
    Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.